{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:13:18Z","timestamp":1761898398668,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.clinre.2016.02.004","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T09:15:32Z","timestamp":1458724532000},"page":"597-604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV\/HCV coinfected, treatment-na\u00efve patients"],"prefix":"10.1016","volume":"40","author":[{"given":"Ying","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feili","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2016.02.004_bib0230","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinre.2016.02.004_bib0235","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/01.aids.0000233577.33973.fa","article-title":"Co-infection with HIV and hepatitis C virus in former plasma\/blood donors: challenge for patient care in rural China","volume":"20","author":"Qian","year":"2006","journal-title":"Aids"},{"key":"10.1016\/j.clinre.2016.02.004_bib0240","doi-asserted-by":"crossref","first-page":"e50343","DOI":"10.1371\/journal.pone.0050343","article-title":"genotype distributions of HIV-infected individuals in Henan and Guangxi","volume":"7","author":"Tian","year":"2012","journal-title":"China. PLoS One"},{"key":"10.1016\/j.clinre.2016.02.004_bib0245","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2016.02.004_bib0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11904-010-0071-3","article-title":"HIV\/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies","volume":"8","author":"Operskalski","year":"2011","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.clinre.2016.02.004_bib0255","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2016.02.004_bib0260","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","article-title":"New horizons in hepatitis C antiviral therapy with direct-acting antivirals","volume":"58","author":"Aghemo","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2016.02.004_bib0265","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.3184","article-title":"Global control of hepatitis C: where challenge meets opportunity","volume":"19","author":"Thomas","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.clinre.2016.02.004_bib0270","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2016.02.004_bib0275","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2016.02.004_bib0280","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0285","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2893.2012.01640.x","article-title":"Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b","volume":"20","author":"Toyota","year":"2013","journal-title":"J Viral Hepat"},{"issue":"Suppl. 2","key":"10.1016\/j.clinre.2016.02.004_bib0290","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S2210-7401(11)70012-2","article-title":"Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus","volume":"35","author":"Piroth","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0295","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2016.02.004_bib0300","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2016.02.004_bib0305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinre.2016.02.004_bib0310","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinre.2016.02.004_bib0315","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0320","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1743-422X-9-245","article-title":"Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients","volume":"9","author":"Paolucci","year":"2012","journal-title":"Virol J"},{"key":"10.1016\/j.clinre.2016.02.004_bib0325","doi-asserted-by":"crossref","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog"},{"issue":"Suppl. 1","key":"10.1016\/j.clinre.2016.02.004_bib0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.12423","article-title":"HCV direct-acting antiviral agents: the best interferon-free combinations","volume":"34","author":"Schinazi","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2016.02.004_bib0335","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2016.02.004_bib0340","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/135965350801300413","article-title":"Mapping natural polymorphisms of hepatitis C virus NS3\/4A protease and antiviral resistance to inhibitors in worldwide isolates","volume":"13","author":"Lopez-Labrador","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.clinre.2016.02.004_bib0345","first-page":"5","article-title":"Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China","volume":"122","author":"Bai","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clinre.2016.02.004_bib0350","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00705-010-0642-z","article-title":"Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients","volume":"155","author":"Peres-da-Silva","year":"2010","journal-title":"Arch Virol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0355","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5501\/wjv.v2.i1.6","article-title":"Hepatitis C virus resistance to new specifically-targeted antiviral therapy: a public health perspective","volume":"2","author":"Salvatierra","year":"2013","journal-title":"World J Virol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0360","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coph.2014.07.016","article-title":"Treatment of HCV infection with the novel NS3\/4A protease inhibitors","volume":"18","author":"De Luca","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0365","first-page":"1","article-title":"Clinically relevant HCV drug resistance mutations Fig. and Tables","volume":"14","author":"HCV Phenotype Working Group, HCV Drug Development Advisory Group","year":"2012","journal-title":"Ann Forum Collab HIV Res"},{"key":"10.1016\/j.clinre.2016.02.004_bib0370","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2005.12.003","article-title":"Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034","volume":"70","author":"Tong","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.clinre.2016.02.004_bib0375","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1128\/AAC.00677-09","article-title":"MK-7009, a potent and selective inhibitor of hepatitis C virus NS3\/4A protease","volume":"54","author":"Liverton","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinre.2016.02.004_bib0380","first-page":"1","article-title":"Clinically relevant HCV drug resistance mutations figure and tables (updated)","volume":"14","author":"Phenotype Working Group DDAG","year":"2012","journal-title":"Ann Forum Collab Hiv Res Volume"},{"key":"10.1016\/j.clinre.2016.02.004_bib0385","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinre.2016.02.004_bib0390","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","article-title":"Epidemiology of viral hepatitis and HIV co-infection","volume":"44","author":"Alter","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0395","doi-asserted-by":"crossref","first-page":"13591","DOI":"10.1128\/JVI.78.24.13591-13599.2004","article-title":"Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china","volume":"78","author":"Zhang","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0400","doi-asserted-by":"crossref","first-page":"e10631","DOI":"10.1371\/journal.pone.0010631","article-title":"High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China","volume":"5","author":"Shang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clinre.2016.02.004_bib0405","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.3748\/wjg.v19.i47.8940","article-title":"Hepatitis C virus protease inhibitor-resistance mutations: our experience and review","volume":"19","author":"Wu","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0410","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1468-1293.2011.00913.x","article-title":"Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV\/HCV-coinfected patients","volume":"12","author":"Trimoulet","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.clinre.2016.02.004_bib0415","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkr581","article-title":"Naturally occurring hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy","volume":"67","author":"Vicenti","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinre.2016.02.004_bib0420","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3851\/IMP2873","article-title":"Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection","volume":"20","author":"Lisboa-Neto","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.clinre.2016.02.004_bib0425","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/QAI.0b013e3181a02fda","article-title":"Detection of hepatitis C mutants with natural resistance to NS3\/4A protease inhibitors in HIV\/HCV-coinfected individuals treated with antiretroviral therapy","volume":"51","author":"Morsica","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clinre.2016.02.004_bib0430","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/jmv.23958","article-title":"Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia","volume":"86","author":"Aissa","year":"2014","journal-title":"J Med Virol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0435","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.clinre.2016.02.004_bib0440","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"EASL Recommendations on Treatment of Hepatitis C 2015","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2016.02.004_bib0445","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2016.02.004_bib0450","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virusres.2013.08.001","article-title":"Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV\/HCV coinfected patients","volume":"177","author":"Bartolini","year":"2013","journal-title":"Virus Res"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740116300304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740116300304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:24:19Z","timestamp":1761895459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740116300304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S2210740116300304"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2016.02.004","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV\/HCV coinfected, treatment-na\u00efve patients","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2016.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}